|
Jun 25
|
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
|
|
Jun 25
|
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
|
|
Jun 24
|
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
|